SGP Stock — SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. (SGP)

Updated October 16, 2026.

SGP is a Stock. Total return is -9.1% over the past 0.7 years, 20.5 points behind SPY at 11.4%.

SpyGlass Pharma is a biopharmaceutical company developing drug delivery systems for chronic eye conditions, including the Bimatoprost Drug Pad-IOL System designed to reduce elevated intraocular pressure by combining medication with intraocular lenses implanted during cataract surgery, and a separate sustained-release implant. The company does not currently have an established distribution schedule. SpyGlass Pharma appeals to investors seeking exposure to early-stage biotech innovation in ophthalmology, though the company remains in development stages without regular income payouts.

SGP performance versus SPY

Price and return data through 2026-10-16.

Total return is -9.1% over the past 0.7 years, 20.5 points behind SPY at 11.4%.

SGP key facts

Asset type

Stock

Asset class

Equity

Inception date

02/06/2026

Distribution frequency

None

Last close

$24.00 (as of 2026-10-16)

Market cap

$802,751,496

Average volume

70647.0

Payout ratio

0.0%

EPS

$-2.55

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SGP risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider SGP — and who may not

It is a weaker fit for investors who need monthly cash flow (SGP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SGP

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions